

paper. However, if additional extensions of time are necessary to prevent abandonment of this application, then such extensions of time are hereby petitioned under 37 C.F.R. § 1.136(a), and any fees required therefor (including fees for net addition of claims) are hereby authorized to be charged to our Deposit Account No. 19-0036.

The amendment does not raise any new issues for consideration and places the claims in condition for allowance or better condition for appeal. Therefore, entry of the amendment is respectfully requested.

Amendments

In the Claims:

Please substitute the following claim 2 for the pending claim 2:

2. (Three Times Amended) A method for determining whether a compound of interest affects an adenylyl cyclase or phospholipase C pathway and therefore is an agonist or antagonist of a receptor which couples to both Gs and Gq proteins comprising:

- (a) providing a cell line which expresses urokinase-type plasminogen activator (u-PA);
- (b) providing an expression vector comprising a nucleotide sequence encoding for a receptor which couples to both Gs and Gq proteins, said receptor not normally expressed in said cell line of step (a);
- (c) introducing said expression vector into said cell line, thereby providing stably transfected cells;

(d) contacting said stably transfected cells and cells of step (a), which do not express said receptor of step (b), with said compound of interest; and
(e) measuring the u-PA activity of the cell culture supernatant of said cells of step (d) by fluorescence or absorbency spectroscopy, thereby determining whether said compound of interest is an agonist or antagonist of a receptor which couples to Gq and Gs proteins.
